H.C. Wainwright Remains Bullish on Delcath Systems (DCTH)

Delcath Systems, Inc. (NASDAQ:DCTH) is one of the best medical device stocks to buy according to analysts. On August 6, H.C. Wainwright analyst Swayampakula Ramakanth maintained a bullish stance on Delcath Systems, Inc. (NASDAQ:DCTH), giving the stock a Buy rating and raising the price target from $29 to $31.

The analyst based the rating upgrade on the solid adoption and performance of Delcath Systems, Inc.’s (NASDAQ:DCTH) HEPZATO product, as the company experienced a notable revenue growth in Q2, primarily attributed to HEPZATO’s sales, which underwent a significant year-over-year increase.

The analyst reasoned that the activation of several treatment centers and plans for further expansion supported this growth, suggesting a solid market presence and considerable potential for continued revenue growth.

Delcath Systems, Inc. (NASDAQ:DCTH) is a specialty pharmaceutical and medical devices company that engages in the treatment of primary and metastatic liver cancers. The company’s products include CHEMOSAT and HEPZATO.

While we acknowledge the potential of DCTH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.